Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indian markets shed early gains
Wed, 4 Feb 11:30 am

Indian stock markets indices shed their initial gains over the last two hours of trade and trading flat. Sectoral indices are trading mixed with metal and pharma stocks leading the gains while auto and capital goods are the leading losers.

The BSE-Sensex is down by 20 points and NSE-Nifty is down by 7 points. BSE Mid Cap index is trading flat and BSE Small Cap index is trading up 0.3%. The rupee is trading at 61.73 to the US dollar.

Oil & Gas sector is trading on a positive note with Cairn India and ONGC being the leading gainers. According to a leading financial daily, the government has decided to exempt upstream oil companies ONGC and Oil India from paying fuel subsidy as long as the crude prices remain below US$ 60 a barrel and proposed to exclude GAIL India from paying any more subsidy this fiscal. The decision comes following a sharp decline in oil prices. State-run oil marketing companies suffer under recovery for selling fuels such as kerosene and LPG at a subsidized cost. There is also an outstanding subsidy of Rs 109 bn on diesel.

Healthcare stocks are all trading in the green barring a few stocks like Aurobindo Pharma and Divis Lab. Ranbaxy Lab and Sun Pharma are the leading gainers. According to a leading financial daily, seven Indian generic pharmaceutical companies have been recommended for suspension by the European Medicines Agency (EMA). The decision follows after questions were raised over the integrity of clinical research data generated at a site operated by Hyderabad-based GVK Biosciences. While the list of suspended medicines comprise the names of several major global generic drug makers, including Teva and Mylan, at least a dozen drugs marketed by Indian companies and their subsidiaries have also been figured in this list.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian markets shed early gains". Click here!